Sandoz GMP Warning Letter: Is The Problem Documentation, Or Leadership?
This article was originally published in The Pink Sheet Daily
Executive Summary
Upper management at Novartis and Sandoz are responsible for repeated cGMP violations at three Sandoz plants, FDA suggests. The agency’s warning letter, aimed at three sites in North Amercia, includes what may become new biolerplate instructions on drug shortages.